Logo for LaunchBio Program: WebinarsLogo for LaunchBio Program: Webinars

Connecting Biotech Entrepreneurs with Knowledge, Capital, and Talent



What Lies Ahead for Nucleic Acid Technology


The culmination of mRNA technology research and development over the past several decades has reached a tipping point that allowed for the rapid commercialization of COVID-19 vaccines. Now, there are a flood of new indications from oncology treatments to flu vaccines that will continue to progress through the clinical process.

As we look ahead, what can we expect from this entirely new generation of medicine? How will this technology continue to evolve? What new ideas will emerge? There are many challenges to be addressed with the current mRNA technology, from efficient and cost effective manufacturing practices to room temperature stable formulations. With mRNA leading the way, new nucleic acid technologies are around the corner to unlock additional potential treatments. Learn from experts in the field as they discuss how these challenges are being met and what lies ahead for nucleic acid technology.


  • Ratish Krishnan

    Ratish Krishnan, Assoc. Dir. and Sr. Strategy Consultant, BioProcessing Novel Modalities

    Ratish Krishnan is a Senior Strategy Consultant in the Novel Modalities BioProcessing group for the Americas at MilliporeSigma. He is passionate about providing solutions to bring treatments to market. A Process Development Scientist by background, he has over 13 years of experience in vaccine, monoclonal antibodies and viral vector modalities from preclinical to late stage process characterization, validation and commercialization activities such as BLA authoring.

  • Frank DeRosa

    Frank DeRosa, PhD - CTO and Head of Research, Sanofi mRNA Center of Excellence

    Frank is currently serving as Chief Technology Officer and Global Head of Research for Sanofi’s mRNA Center of Excellence (CoE). He has played a critical role in the creation, development, application and expansion of its messenger RNA (mRNA) therapeutics (MRT) platform including in vivo applications, delivery technology, and next-generation nucleic acid strategies as well as new manufacturing processes through to GMP stage. Prior to joining the CoE, he was the ChiefTechnology Officer at Translate Bio, which was acquired by Sanofi in 2021.

  • Nathaniel Wang

    Nathaniel Wang, PhD, Founder and CEO, Replicate Bioscience

    Dr. Nathaniel Wang is the CEO at Replicate Bioscience and cofounder of the company. He has over 15 years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery, including the development of the Replicate srRNA platform. He is also a recognized expert in the fields of immuno-oncology and infectious disease.

    Prior to Replicate Bioscience, Dr. Wang was head of the RNA Medicines business unit at Synthetic Genomics, where he developed a self-replicating RNA platform asset.

  • Julian Mochayedi

    Julian Mochayedi, PhD, Strategic Marketing Manager for mRNA Solutions, MilliporeSigma

    Dr. Julian Mochayedi is the strategic marketing manager for mRNA solutions, and responsible for the strategy development and positioning of the mRNA CDMO offering based on the acquisition of AmpTec GmbH, a leading mRNA CDMO. Prior to joining Merck KGaA Darmstadt Germany (operating as MilliporeSigma in the US and Canada) he gained experience in translational research with profound expertise in the areas of novel modalities and in vivo gene editing. Julian holds a M.Sc. in bioprocess development and a Ph.D. in translational immunology from Heidelberg University

no tags added to this event